Literature DB >> 33983584

Patient-Derived Xenograft Models in Breast Cancer Research.

Deukchae Na1, Hyeong-Gon Moon2.   

Abstract

Patient-derived xenograft (PDX) model can be used as a platform to study the individual patient's sensitivity to targeted agents as well as its ability to guide our understanding in various aspects of tumor biology including the tumor's clonal evolution and interaction with microenvironment. In this chapter, we review the history of PDX models in various tumor types. Additionally, we highlight the key studies that suggested potential value of PDX models in cancer treatment. Specifically, we will briefly introduce several studies on the issue of PDX models for precision medicine. In latter part of this chapter, we focus on the studies that used PDX models to investigate the molecular biology of breast cancer that underlies the process of drug resistance and tumor metastasis. Also, we will address our own experience in developing PDX models using breast cancer tissues from Korean breast cancer patients.

Entities:  

Keywords:  Breast cancer; Drug resistance; Genetics; Microenvironment; Patient-derived xenograft model; Precision medicine

Mesh:

Substances:

Year:  2021        PMID: 33983584     DOI: 10.1007/978-981-32-9620-6_14

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  72 in total

1.  Absence of thymus in a mouse mutant.

Authors:  E M Pantelouris
Journal:  Nature       Date:  1968-01-27       Impact factor: 49.962

2.  Establishment of human tumor xenografts in immunodeficient mice.

Authors:  Christopher L Morton; Peter J Houghton
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

Review 3.  Organoid development in cancer genome discovery.

Authors:  Dong Gao; Yu Chen
Journal:  Curr Opin Genet Dev       Date:  2015-03-19       Impact factor: 5.578

4.  Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells.

Authors:  Leonard D Shultz; Bonnie L Lyons; Lisa M Burzenski; Bruce Gott; Xiaohua Chen; Stanley Chaleff; Malak Kotb; Stephen D Gillies; Marie King; Julie Mangada; Dale L Greiner; Rupert Handgretinger
Journal:  J Immunol       Date:  2005-05-15       Impact factor: 5.422

5.  Co-clinical Assessment of Tumor Cellularity in Pancreatic Cancer.

Authors:  Irina Heid; Katja Steiger; Marija Trajkovic-Arsic; Marcus Settles; Manuela R Eßwein; Mert Erkan; Jörg Kleeff; Carsten Jäger; Helmut Friess; Bernhard Haller; Andreas Steingötter; Roland M Schmid; Markus Schwaiger; Ernst J Rummeny; Irene Esposito; Jens T Siveke; Rickmer F Braren
Journal:  Clin Cancer Res       Date:  2016-09-23       Impact factor: 12.531

6.  A severe combined immunodeficiency mutation in the mouse.

Authors:  G C Bosma; R P Custer; M J Bosma
Journal:  Nature       Date:  1983-02-10       Impact factor: 49.962

7.  Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice.

Authors:  L D Shultz; P A Schweitzer; S W Christianson; B Gott; I B Schweitzer; B Tennent; S McKenna; L Mobraaten; T V Rajan; D L Greiner
Journal:  J Immunol       Date:  1995-01-01       Impact factor: 5.422

8.  The promise of patient-derived xenografts: the best laid plans of mice and men.

Authors:  Scott Kopetz; Robert Lemos; Garth Powis
Journal:  Clin Cancer Res       Date:  2012-08-21       Impact factor: 12.531

Review 9.  SCID mouse models of human stem cell engraftment.

Authors:  D L Greiner; R A Hesselton; L D Shultz
Journal:  Stem Cells       Date:  1998       Impact factor: 6.277

Review 10.  Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century.

Authors:  Samuel A Williams; Wade C Anderson; Marianne T Santaguida; Scott J Dylla
Journal:  Lab Invest       Date:  2013-08-05       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.